Latest News

Every day brings us closer to finding a cure for cardiovascular disease - the UK's number one killer. Here is the latest from our research laboratories.
TAGGED IN
Clear
atherosclerosis

HRI welcomes Dr Ashish Misra as Unit Leader

HRI welcomes Dr Ashish Misra as Unit Leader

The Heart Research Institute welcomes Dr Ashish Misra as Unit Leader of the Atherosclerosis and Vascular Remodelling Group.

Read more

Neutrophils in acute coronary syndrome

Neutrophils in acute coronary syndrome
HRI researchers Dr Rahul Kurup and Associate Professor Sanjay Patel from the Cell Therapeutics Group recently published a review of the role of neutrophils in acute coronary syndrome. With abundant data demonstrating this role, this presents opportunities to develop novel diagnostic and prognostic biomarkers and therapeutic agents that specifically target neutrophils.
Read more

Stopping atherosclerosis in its tracks

Stopping atherosclerosis in its tracks
A new treatment for atherosclerosis could soon be in sight, with an HRI study finding that progression of the common condition could be slowed using the chemokine binding protein ‘M3’.
Read more

Meet the team: Imala Alwis

Meet the team: Imala Alwis

Imala Alwis is a senior research officer at the Heart Research Institute, working in the Thrombosis group. He shares his personal story about his connection with heart disease.

"Heart disease has affected me personally. My dad was in his mid fifties when he had triple bypass surgery. He led a very healthy lifestyle and he was only diagnosed during a routine medical check up."

Read more

HRI awarded prestigious Ramaciotti grant

HRI awarded prestigious Ramaciotti grant

Dr Sanjay Patel, Group Leader at the Heart Research Institute, has been awarded a highly prestigious Ramaciotti Grant to pursue his work developing a cost-effective therapy to prevent heart attack and stroke.

The five Ramaciotti Health Investment Grants of $150,000 are awarded to autonomous early career scientists to support health or medical research with a potential path to clinical application within five years.

Read more